
The bonus scheme of Novo Nordisk CEO and President Lars Fruergaard Jørgensen is not tied in with the share price of the Danish pharmaceutical company, which comes as a surprise to German investment bank Berenberg.
The bank has analyzed the salaries of CEOs in 12 of the world's largest pharmaceutical companies, and Fruergaard Jørgensen's bonus scheme is the only one that does not correlate with the development of the share price of his company.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app